A novel molecular classification system based on the molecular feature score identifies patients sensitive to immune therapy and target therapy
The four-layer classification scheme enhances the understanding of HCC heterogeneity, and we also provide robust predictive software for predicting classifications and prognoses. Notably, C1 is more sensitive to anti-PD1 therapies and FTCD is a promising therapeutic target, particularly for C1 and C4. These findings provide new insights into classification-guided precision medicine.
Authors
- Guoliang Shao (ORCID: https://orcid.org/0000-0002-6697-8488)
- Pengfei Zhang
- Han Zhou (ORCID: https://orcid.org/0000-0001-6867-9978)
- Jinghao Wang (ORCID: https://orcid.org/0000-0001-8696-6911)
- Yinan Ding (ORCID: https://orcid.org/0000-0002-1010-2874)
- Dinghu Zhang
- Yang Li (ORCID: https://orcid.org/0000-0002-1751-1742)
- Xiaoxia Wu (ORCID: https://orcid.org/0000-0001-9375-5266)
Institutions
- University of Science and Technology of China (CN)
- Chinese Academy of Sciences (CN)
- Inner Mongolia University (CN)
- Zhejiang Cancer Hospital (CN)
- University of Chinese Academy of Sciences (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-11-26
- DOI
- https://doi.org/10.3389/fimmu.2024.1466069
- Citations
- 1
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.37